Therapie最新文献

{"title":"When generative AI goes off the rails and leads to adverse drug reactions.","authors":"Romain Barus, Claire de Canecaude, Pauline Schiro, Camille Potey, Jeanne Neez, Anthony Facile, Marlène Damin-Pernik, François Montastruc","doi":"10.1016/j.therap.2026.07.001","DOIUrl":"https://doi.org/10.1016/j.therap.2026.07.001","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated depressive disorders and suicidality with finasteride use for androgenetic alopecia: A call for enhanced vigilance","authors":"Hélène Géniaux, Marie-Laure Laroche","doi":"10.1016/j.therap.2025.09.004","DOIUrl":"10.1016/j.therap.2025.09.004","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the clinical characteristics of depressive disorders and suicidality not associated with sexual dysfunction among users of finasteride 1<!--> <!-->mg/day for androgenetic alopecia.</div></div><div>To describe the clinical characteristics of depressive disorders and suicidality not associated with sexual dysfunction among users of finasteride 1<!--> <!-->mg/day for androgenetic alopecia.</div><div><h3>Methods</h3><div>A retrospective descriptive analysis was conducted using data from the French National Pharmacovigilance Database (BNPV) from 1985 to May 2024. Cases were selected based on the presence of depressive or suicidal symptoms, classified in Medical Dictionary for Regulatory Activities (MedDRA) high-level group terms, with no co-reported sexual dysfunction.</div></div><div>A retrospective descriptive analysis was conducted using data from the French National Pharmacovigilance Database (BNPV) from 1985 to May 2024. Cases were selected based on the presence of depressive or suicidal symptoms, classified in Medical Dictionary for Regulatory Activities (MedDRA) high-level group terms, with no co-reported sexual dysfunction.</div><div><h3>Results</h3><div>Forty cases of depression or suicidality were identified in men treated with finasteride, with a median age of 31<!--> <!-->years. Most cases (62.5%) were classified as serious. In half of the cases, symptoms occurred within 9<!--> <!-->months of treatment initiation. Suicidality (ideation or attempts) was present in 40% of cases. Among patients who discontinued treatment, 45.2% reported symptom improvement. In unresolved cases (<em>n</em> <!-->=<!--> <!-->10), the median persistence of symptoms after withdrawal was 20.2<!--> <!-->months. A positive rechallenge was observed in two patients. Only 22.5% had a personal or family psychiatric history, and 17.5% reported a significant impact on quality of life.</div></div><div>Forty cases of depression or suicidality were identified in men treated with finasteride, with a median age of 31<!--> <!-->years. Most cases (62.5%) were classified as serious. In half of the cases, symptoms occurred within 9<!--> <!-->months of treatment initiation. Suicidality (ideation or attempts) was present in 40% of cases. Among patients who discontinued treatment, 45.2% reported symptom improvement. In unresolved cases (<em>n</em> <!-->=<!--> <!-->10), the median persistence of symptoms after withdrawal was 20.2<!--> <!-->months. A positive rechallenge was observed in two patients. Only 22.5% had a personal or family psychiatric history, and 17.5% reported a significant impact on quality of life.</div><div><h3>Conclusion</h3><div>While adverse psychiatric drug reactions, including depressive symptoms and suicidality, are often reported in conjunction with sexual dysfunction, this study highlights the severity of depressive effects associated with finasteride, particularly the risk of suicidality even in the absence of associated","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 303-310"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin prescription in hospitalized patients with renal impairment: What about in real life? A cross-sectional study","authors":"Léa Tardy, Marie-Noelle Beyens, Florelle Bellet, Marlène Damin-Pernik","doi":"10.1016/j.therap.2026.01.006","DOIUrl":"10.1016/j.therap.2026.01.006","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 365-368"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Évaluation de la qualité des preuves citées dans les guides de pratique clinique français d’infectiologie en soins primaires","authors":"Eulalie Gillet-Lecourt, Kenza Akhamlich, Mikaël Bouchard, Mathilde François, Irène Supper, Rémy Boussageon","doi":"10.1016/j.therap.2025.10.004","DOIUrl":"10.1016/j.therap.2025.10.004","url":null,"abstract":"<div><h3>Objectif</h3><div>Évaluer le niveau de preuve des recommandations d’antibiothérapie pour les soins primaires.</div></div><div>Évaluer le niveau de preuve des recommandations d’antibiothérapie pour les soins primaires.</div><div><h3>Méthode</h3><div>Après recueil des guides de pratique clinique (GPC) listés sur le site Antibioclic® (<span><span>https://antibioclic.com</span><svg><path></path></svg></span>) pour chaque recommandation portant sur la prescription ou non d’un antibiotique, une évaluation a été réalisée sur la mention ou non du GRADE de la Haute autorité de santé (HAS) : A, B, C, ou avis d’expert (AE). Les sources citées par les GPC ont été étudiées. Les recommandations et études devaient répondre à la question « faut-il ou non prescrire une antibiothérapie dans cette situation ? ». Les réponses possibles étaient « oui », « non », ou « oui conditionnel », c’est-à-dire, prescription différée. Le critère de jugement principal était le pourcentage de recommandations pour lesquelles des études étaient citées, comparativement au GRADE indiqué.</div></div><div>Après recueil des guides de pratique clinique (GPC) listés sur le site Antibioclic® (<span><span>https://antibioclic.com</span><svg><path></path></svg></span>) pour chaque recommandation portant sur la prescription ou non d’un antibiotique, une évaluation a été réalisée sur la mention ou non du GRADE de la Haute autorité de santé (HAS) : A, B, C, ou avis d’expert (AE). Les sources citées par les GPC ont été étudiées. Les recommandations et études devaient répondre à la question « faut-il ou non prescrire une antibiothérapie dans cette situation ? ». Les réponses possibles étaient « oui », « non », ou « oui conditionnel », c’est-à-dire, prescription différée. Le critère de jugement principal était le pourcentage de recommandations pour lesquelles des études étaient citées, comparativement au GRADE indiqué.</div><div><h3>Résultats</h3><div>Au total, 152 recommandations issues de 49 GPC sur la prescription d’antibiotiques ont été analysées. Au total, 71,7 % ne mentionnaient pas de niveau de preuve, 3,3 % étaient classées de GRADE A et 9,2 % de GRADE B. En examinant les études justifiant les recommandations, des preuves de haute qualité ont été identifiées pour 7,9 % des recommandations, tandis que 80,9 % d’entre elles n’avaient pas d’études référencées.</div></div><div>Au total, 152 recommandations issues de 49 GPC sur la prescription d’antibiotiques ont été analysées. Au total, 71,7 % ne mentionnaient pas de niveau de preuve, 3,3 % étaient classées de GRADE A et 9,2 % de GRADE B. En examinant les études justifiant les recommandations, des preuves de haute qualité ont été identifiées pour 7,9 % des recommandations, tandis que 80,9 % d’entre elles n’avaient pas d’études référencées.</div><div><h3>Conclusion</h3><div>La plupart des recommandations françaises sur la prescription d’antibiotiques pour les soins primaires ne fournissent pas le niveau de preuve les justifiant.</div></di","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 323-328"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145459821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluoxetine-induced lower limb ecchymosis in an adolescent: A case report and literature review","authors":"Thomas Darque, Clément Pruvot, Paul Nadin, Paola Sanchez-Pena, Myrtille Hamm, Juliette Miquel","doi":"10.1016/j.therap.2025.09.003","DOIUrl":"10.1016/j.therap.2025.09.003","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 349-351"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risque d’ulcérations cutanéo-muqueuses lié au nicorandil : données récentes de la base nationale de pharmacovigilance française et du programme de médicalisation des systèmes d’information (NICORUC)","authors":"Liliane Batty, Joanna Lapalus, Elsa Trime, Pauline Schiro, Romain Barus, Didier Fabre, Johana Béné, Julien Moragny, Viktoryia Prontskus, Haleh Bagheri","doi":"10.1016/j.therap.2025.08.001","DOIUrl":"10.1016/j.therap.2025.08.001","url":null,"abstract":"<div><h3>Objectif</h3><div>Le risque d’ulcérations cutanéo-muqueuses associées au nicorandil reste un effet indésirable (EI) bien décrit. En cas de suspicion de cet EI, un diagnostic précoce et un arrêt immédiat du nicorandil sont recommandés. L’objectif de ce travail est d’actualiser les données de pharmacovigilance.</div></div><div>Le risque d’ulcérations cutanéo-muqueuses associées au nicorandil reste un effet indésirable (EI) bien décrit. En cas de suspicion de cet EI, un diagnostic précoce et un arrêt immédiat du nicorandil sont recommandés. L’objectif de ce travail est d’actualiser les données de pharmacovigilance.</div><div><h3>Méthodes</h3><div>Deux sources de données ont été utilisées sur la période de janvier 2017 à fin novembre 2024 : les déclarations de pharmacovigilance enregistrées dans la base nationale de pharmacovigilance (BNPV) et les dossiers en lien avec cet EI et le nicorandil à partir des données du PMSI (programme de médicalisation des systèmes d’information) du centre hospitalier universitaire de Toulouse.</div></div><div>Deux sources de données ont été utilisées sur la période de janvier 2017 à fin novembre 2024 : les déclarations de pharmacovigilance enregistrées dans la base nationale de pharmacovigilance (BNPV) et les dossiers en lien avec cet EI et le nicorandil à partir des données du PMSI (programme de médicalisation des systèmes d’information) du centre hospitalier universitaire de Toulouse.</div><div><h3>Résultats</h3><div>Nous avons collecté un total de 62 cas : 28 cas enregistrés dans la BNPV et 34 cas supplémentaires identifiés dans le PMSI (<em>n</em> <!-->=<!--> <!-->62). Aucun des cas du PMSI n’a été signalé au centre de pharmacovigilance de Toulouse. Les patients étaient âgés de 56 à 97<!--> <!-->ans (sex-ratio 0,94). Le nicorandil a été arrêté chez 36 patients (immédiatement pour 11 d’entre eux). Six patients sont décédés, dont trois malgré l’arrêt du nicorandil, principalement en raison de complications digestives ou de sepsis. Dans 61 % des cas de la BNPV (<em>n</em> <!-->=<!--> <!-->17) l’EI était classé comme grave et le délai médian de survenue de l’EI était de 407<!--> <!-->jours (IQR : 123 à 1826<!--> <!-->jours). Les ulcérations cutanées étaient principalement localisées sur les membres inférieurs et les ulcérations muqueuses affectaient majoritairement les muqueuses buccale et digestive.</div></div><div>Nous avons collecté un total de 62 cas : 28 cas enregistrés dans la BNPV et 34 cas supplémentaires identifiés dans le PMSI (<em>n</em> <!-->=<!--> <!-->62). Aucun des cas du PMSI n’a été signalé au centre de pharmacovigilance de Toulouse. Les patients étaient âgés de 56 à 97<!--> <!-->ans (sex-ratio 0,94). Le nicorandil a été arrêté chez 36 patients (immédiatement pour 11 d’entre eux). Six patients sont décédés, dont trois malgré l’arrêt du nicorandil, principalement en raison de complications digestives ou de sepsis. Dans 61 % des cas de la BNPV (<em>n</em> <!-->=<!--> <!-->17) l’EI était classé c","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 297-302"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemsex, drugs and consequences: A short review","authors":"Diane Le Bouëdec,&nbsp;Romain Pelletier,&nbsp;François Bénézit,&nbsp;Raphaël Pangui,&nbsp;Isabelle Morel,&nbsp;Thomas Gicquel","doi":"10.1016/j.therap.2025.11.006","DOIUrl":"10.1016/j.therap.2025.11.006","url":null,"abstract":"<div><div>Chemsex refers to the intentional use of psychoactive substances to enhance sexual expériences. It often involves prolonged sexual sessions, multiple partners, and the use of drugs such as GHB, synthetic cathinones, and erectile dysfunction medications. Prevalence estimates vary widely across studies, ranging from 9 to 21% in Europe, reflecting heterogeneity in definitions and populations studied. This practice can be associated to serious health risks, including substance addiction, psychiatric disorders, and increased rates of sexually transmitted infections (STIs), notably HIV and hepatitis C. Intravenous drug use during sex (“slamming”) carries particularly high risks. Despite its initial emergence in men who have sex with men (MSM) communities, chemsex is also reported among heterosexual and transgender populations. Effective responses require non-judgmental, multidisciplinary support, combining harm reduction, mental health care, and STI prevention. Healthcare professionals must be trained to recognize and address chemsex-related issues. Further research is needed to better define the phenomenon and inform public health strategies. This article provides a brief review of the characteristics, epidemiology, and potential addictive, infectious, and psychological consequences of chemsex.</div></div><div>Chemsex refers to the intentional use of psychoactive substances to enhance sexual expériences. It often involves prolonged sexual sessions, multiple partners, and the use of drugs such as GHB, synthetic cathinones, and erectile dysfunction medications. Prevalence estimates vary widely across studies, ranging from 9 to 21% in Europe, reflecting heterogeneity in definitions and populations studied. This practice can be associated to serious health risks, including substance addiction, psychiatric disorders, and increased rates of sexually transmitted infections (STIs), notably HIV and hepatitis C. Intravenous drug use during sex (“slamming”) carries particularly high risks. Despite its initial emergence in men who have sex with men (MSM) communities, chemsex is also reported among heterosexual and transgender populations. Effective responses require non-judgmental, multidisciplinary support, combining harm reduction, mental health care, and STI prevention. Healthcare professionals must be trained to recognize and address chemsex-related issues. Further research is needed to better define the phenomenon and inform public health strategies. This article provides a brief review of the characteristics, epidemiology, and potential addictive, infectious, and psychological consequences of chemsex.</div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 287-296"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145744409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive outer retinal necrosis complicating aseptic meningitis due to varicella zoster virus reactivation 44 days after infusion of natalizumab","authors":"Hidaya Drissi Oudghiri,&nbsp;Thomas Ferreira De Moura,&nbsp;Brahim Azzouz,&nbsp;Catherine Feliu,&nbsp;Michael Hoang,&nbsp;Aurélie Brunet,&nbsp;Véronique Brodard,&nbsp;Yohan N’Guyen","doi":"10.1016/j.therap.2025.09.001","DOIUrl":"10.1016/j.therap.2025.09.001","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 346-349"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixtures and dilutions of commercial solutions for oral drops: What happens in these cocktails?","authors":"Caroline Castera-Ducros,&nbsp;Romain Paoli-Lombardo,&nbsp;Ikram Zaddam,&nbsp;Cyril Fersing,&nbsp;Charleric Bornet,&nbsp;Patrice Vanelle,&nbsp;Pascal Rathelot,&nbsp;Christophe Curti","doi":"10.1016/j.therap.2025.11.002","DOIUrl":"10.1016/j.therap.2025.11.002","url":null,"abstract":"<div><h3>Background</h3><div>Physicochemical incompatibilities of parenteral drugs are frequently studied and reported, but are rarely documented for liquid oral drugs. However, in clinical practices, nurses may perform mixtures of several liquid oral formulations. Although such practices are not recommended, there is a lack of scientific evidence to support this statement.</div></div><div>Physicochemical incompatibilities of parenteral drugs are frequently studied and reported, but are rarely documented for liquid oral drugs. However, in clinical practices, nurses may perform mixtures of several liquid oral formulations. Although such practices are not recommended, there is a lack of scientific evidence to support this statement.</div><div><h3>Objective</h3><div>We aimed to study potential incompatibilities of the most dispensed commercial liquid oral formulations in a psychiatric ward.</div></div><div>We aimed to study potential incompatibilities of the most dispensed commercial liquid oral formulations in a psychiatric ward.</div><div><h3>Methods</h3><div>First, a bibliographic analysis was performed. Then, 1:1 mixtures of one commercial liquid specialty and tap water and 1:1:1 mixtures of two commercial formulations and water were realized and controlled both visually and analytically. When a precipitate was formed, the mixture was considered incompatible.</div></div><div>First, a bibliographic analysis was performed. Then, 1:1 mixtures of one commercial liquid specialty and tap water and 1:1:1 mixtures of two commercial formulations and water were realized and controlled both visually and analytically. When a precipitate was formed, the mixture was considered incompatible.</div><div><h3>Results</h3><div>A table of oral liquid drug incompatibilities was compiled, and the need for pharmaceutical expertise on this subject was discussed.</div></div><div>A table of oral liquid drug incompatibilities was compiled, and the need for pharmaceutical expertise on this subject was discussed.</div><div><h3>Conclusion</h3><div>This work is the first report of oral liquid drugs’ physicochemical incompatibilities and can lead to an improvement in clinical practices.</div></div><div>This work is the first report of oral liquid drugs’ physicochemical incompatibilities and can lead to an improvement in clinical practices.</div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 311-317"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Les « cannabis edibles » : comestibles sans risque ? À propos d’une série de 5 cas","authors":"Sandra Thorigné,&nbsp;Véronique Ferey,&nbsp;Elodie Saussereau,&nbsp;Sabrina Cherki,&nbsp;Reynald Le Boisselier","doi":"10.1016/j.therap.2025.11.007","DOIUrl":"10.1016/j.therap.2025.11.007","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"81 4","pages":"Pages 361-365"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}